Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.98 USD

42.98
1,317,948

+0.30 (0.70%)

Updated May 3, 2024 04:00 PM ET

After-Market: $42.99 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for QGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

QIAGEN N.V. [QGEN]

Reports for Purchase

Showing records 201 - 220 ( 234 total )

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 201

11/04/2013

Company Report

Pages: 11

3Q13 Recap - Ex-US HPV Tenders Help Results Edge Higher - Molecular Business Fine - Is FCF Improvement Sustainable? - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 202

10/24/2013

Company Report

Pages: 9

Expecting In-line 3Q13 - Looking for Better Pharma Momentum & Ok System Sales

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 203

10/15/2013

Industry Report

Pages: 10

Technical Analysis - Biotech Stocks Ignored and Oversold, Offering Good Entry

Provider: Drexel Hamilton, LLC

Analyst: SINE B

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 204

08/16/2013

Company Report

Pages: 11

Retooling Model Post 2Q13 Results - More Optimistic on 2014 Leverage Story vs Street - Not Yet Convinced on 2014 Sales - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 205

07/30/2013

Daily Note

Pages: 9

2Q13 Pre-conference Call Summary - In-line Results

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 206

07/28/2013

Company Report

Pages: 8

Expecting In-line 2Q13 - Expecting Solid Dx System Placements & So-So Tools - Cancer Dx Acceleration Could Makes Us More Constructive

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 207

05/16/2013

Daily Note

Pages: 7

Somewhat More Positive Following Investor Meetings - Good Tone On System Placements and TB Franchise - Maintaining NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 208

04/30/2013

Company Report

Pages: 8

1Q13 First Read - Results a Tad Soft - Solid Diagnostics Growth Offset by Challenging Academia - Guidance Trimmed Due to Sequester - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 209

04/30/2013

Company Report

Pages: 10

1Q13 Recap - Results A Bit Soft - Equipment Sales Missed Our Forecast Due to Sequester

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 210

04/24/2013

Company Report

Pages: 8

1Q13 Preview - Expecting In-line Results - Eyes on Strength from Recent M&A and KRAS Momentum - Still Waiting for Sequencer Performance Specs

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 211

04/09/2013

Company Report

Pages: 7

Tightening Our 1Q13 Revenue Estimate Due to Greater Fx Impact and More Realistic Flu & Cold Season Benefit

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 212

02/21/2013

Daily Note

Pages: 7

Next-Gen Sequencer Unveiled at AGBT As Planned - Emphasis on Workflow for Clinical Apps - Specs Expected Friday - Limited 2013 Revs - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 213

01/31/2013

Company Report

Pages: 11

4Q12 Recap - Solid Top-line Driven By Molecular Dx & Applied Testing.

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 214

01/29/2013

Daily Note

Pages: 7

3Q12 Pre-conference Call Recap - Sales Solid Likely Due to Dx

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 215

01/28/2013

Company Report

Pages: 7

4Q12 Preview - Expecting a Slight Beat Driven by Late December Disease Activity

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 216

11/05/2012

Daily Note

Pages: 8

3Q12 Pre-conference Call Recap - Sales In line - EPS Beats By $0.02 Due to Lower Tax Rate - Acquisitions Perform Fine - BRIC Growth Solid - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 217

11/05/2012

Company Report

Pages: 10

3Q12 results in line with expectations.

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 218

07/26/2012

Company Report

Pages: 10

2Q12 Recap - Encouraging Tone Overall - Very Strong Instrument Orders Drive Beat

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 219

07/25/2012

Daily Note

Pages: 8

2Q12 First Blush - Sales & EPS Beat Consensus on Strong System Sales

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 220

07/23/2012

Company Report

Pages: 8

Expecting In-line 2Q12 - Sequencing Strategy Intriguing

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party